Zobrazeno 1 - 10 of 30 pro vyhledávání: '"Alberto Russu"'
1
Akademický článek
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine
Autor: Parul Patel, Paula Teichner, Emilie Elliot, Marta Boffito, Milena Murray, Joseph W. Polli, Mark Baker, Susan L. Ford, Kelong Han, Alberto Russu, Herta Crauwels, Ronald D. D’Amico, William R. Spreen, Jean van Wyk
Publikováno v: Therapeutic Advances in Infectious Disease, Vol 10 (2023)
Cabotegravir (CAB) and rilpivirine (RPV) is the first complete long-acting (LA) injectable regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression in people with HIV-1 who are virologically suppressed on a stabl
Externí odkaz: https://doaj.org/article/6ced232122ea4106b728a36f74e12256
Zobrazit plný text záznamu
2
Akademický článek
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
Autor: Gerald Novak, Johannes Rolf Streffer, Maarten Timmers, David Henley, H. Robert Brashear, Jennifer Bogert, Alberto Russu, Luc Janssens, Ina Tesseur, Luc Tritsmans, Luc Van Nueten, Sebastiaan Engelborghs
Publikováno v: Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-16 (2020)
Abstract Background Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer’s disease (AD). The long-term safety and effect of atabecestat on cognitive p
Externí odkaz: https://doaj.org/article/247a92d1c31a4e54b2ea3153ba65cedc
Zobrazit plný text záznamu
3
Akademický článek
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
Autor: Maarten Timmers, Johannes Rolf Streffer, Alberto Russu, Yushin Tominaga, Hiroko Shimizu, Ayako Shiraishi, Kanaka Tatikola, Pascale Smekens, Anne Börjesson-Hanson, Niels Andreasen, Jorge Matias-Guiu, Miquel Baquero, Mercè Boada, Ina Tesseur, Luc Tritsmans, Luc Van Nueten, Sebastiaan Engelborghs
Publikováno v: Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-18 (2018)
Abstract Background β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer’s disease (AD), but treatment initiation may need to be very early. We present proof of mechanism of atabecestat (also known
Externí odkaz: https://doaj.org/article/29adc1da679f4c53b4ec494c0c1dcf5e
Zobrazit plný text záznamu
4
Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations
Autor: Yu Feng, Mahesh N. Samtani, Maju Mathews, Adam Savitz, Alberto Russu, Srihari Gopal
Publikováno v: Journal of Clinical Psychopharmacology. 39:567-574
Background Pharmacokinetic-pharmacodynamic (PK/PD) models were developed to describe the relationship between the time course of paliperidone plasma concentrations and the risk of relapse of schizophrenia symptoms following administration of paliperi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e194e9431a76a01ef3013dd476bdaeec
https://doi.org/10.1097/jcp.0000000000001137
Zobrazit plný text záznamu
5
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: A randomized, double-blind, placebo-controlled study and a two-period extension study
Autor: Johannes Streffer, Luc Tritsmans, David Henley, Ina Tesseur, Maarten Timmers, Jennifer Bogert, Luc Janssens, Alberto Russu, Luc Van Nueten, Gerald Novak, H. Robert Brashear, Sebastiaan Engelborghs
Publikováno v: Alzheimer's Research & Therapy
Alzheimer's research & therapy
Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-16 (2020)
Background Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer’s disease (AD). The long-term safety and effect of atabecestat on cognitive performanc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f31ce74cbd1876b7f1e8281e08b9dd6a
https://doi.org/10.21203/rs.2.22841/v2
Zobrazit plný text záznamu
7
Bayesian sequential integration within a preclinical PK-PD modeling framework: Lessons learned
Autor: Fabiola La Gamba, Tom Jacobs, Helena Geys, Thomas Jaki, Jan Serroyen, Moreno Ursino, Alberto Russu, Christel Faes
Publikováno v: Pharmaceutical Statistics
The present manuscript aims to discuss the implications of sequential knowledge integration of small preclinical trials in a Bayesian PK-PD framework. While, at first sight, a Bayesian PK-PD framework seems to be a natural framework to allow for sequ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ea322df6cf52c5abac491bd8f36aad1
Zobrazit plný text záznamu
8
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor
Autor: Marc Mercken, John Slemmon, Luc Van Nueten, Hans Stieltjes, Bianca Van Broeck, Enchi Liu, John Kemp, Maarten Timmers, Vikash K. Sinha, Jennifer Bogert, Luc Tritsmans, Katja De Waepenaert, Steven Ramael, Dieder Moechars, Sebastiaan Engelborghs, Alberto Russu, Leslie M. Shaw, Johannes Streffer
Publikováno v: Alzheimer's & Dementia : Translational Research & Clinical Interventions
Objectives Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, JNJ-54861911, were assessed after single and multiple dosing in healthy participants. Methods Tw
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::940d96293de7d0f3c049899461840d13
https://doi.org/10.1016/j.trci.2016.08.001
Zobrazit plný text záznamu
9
Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy
Autor: Partha Nandy, David Hough, Ellen Z. Baum, Mahesh N. Samtani, Alberto Russu, Bart Remmerie, Paulien Ravenstijn, Peter D'hoore, Srihari Gopal, Adam Savitz, An Vermeulen
Publikováno v: British Journal of Clinical Pharmacology. 82:1364-1370
Aims To prospectively select the dose of the paliperidone palmitate 3-month (PP3M) formulation, using a pharmacometric bridging strategy based on the paliperidone palmitate 1-month (PP1M) formulation previously approved for schizophrenia treatment. M
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9d802e5f6f781a717d55279b1f98c6aa
https://doi.org/10.1111/bcp.13050
Zobrazit plný text záznamu
10
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease
Autor: Pascale Smekens, Niels Andreasen, Mercè Boada, Yushin Tominaga, Luc Van Nueten, Alberto Russu, Jorge Matías-Guiu, Miquel Baquero, Sebastiaan Engelborghs, Ina Tesseur, Johannes Streffer, Ayako Shiraishi, Kanaka Tatikola, Hiroko Shimizu, Luc Tritsmans, Maarten Timmers, Anne Börjesson-Hanson
Publikováno v: Alzheimers Research & Therapy
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-18 (2018)
Alzheimer's research & therapy
Alzheimer's Research & Therapy
Background β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer’s disease (AD), but treatment initiation may need to be very early. We present proof of mechanism of atabecestat (also known as JNJ-5
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a6297d9eaeedbe80ecf85135b8bd35
https://doi.org/10.1186/s13195-018-0415-6
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje